These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Combined metformin-associated lactic acidosis and euglycemic ketoacidosis. Schwetz V; Eisner F; Schilcher G; Eller K; Plank J; Lind A; Pieber TR; Mader JK; Eller P Wien Klin Wochenschr; 2017 Sep; 129(17-18):646-649. PubMed ID: 28865058 [TBL] [Abstract][Full Text] [Related]
23. Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis. Hughes CA; Taylor GD Ann Pharmacother; 2001; 35(7-8):877-80. PubMed ID: 11485138 [TBL] [Abstract][Full Text] [Related]
24. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Erondu N; Desai M; Ways K; Meininger G Diabetes Care; 2015 Sep; 38(9):1680-6. PubMed ID: 26203064 [TBL] [Abstract][Full Text] [Related]
25. Lessons from the bedside: ketoacidosis and SGLT2 inhibitors. Chow YY; Worsley R; Topliss DJ Med J Aust; 2016 Aug; 205(4):191-2. PubMed ID: 27510353 [No Abstract] [Full Text] [Related]
27. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin. van Niekerk C; Wallace J; Takata M; Yu R BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30131409 [TBL] [Abstract][Full Text] [Related]
29. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Lapuerta P; Zambrowicz B; Strumph P; Sands A Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134 [TBL] [Abstract][Full Text] [Related]
30. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686. Dhatariya K Diabetes Care; 2016 Jan; 39(1):e18. PubMed ID: 26696665 [No Abstract] [Full Text] [Related]
31. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686. Ou HY; Karnchanasorn R; Chuang LM; Chiu KC Diabetes Care; 2015 Nov; 38(11):e198. PubMed ID: 26494820 [No Abstract] [Full Text] [Related]
32. Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686. Erondu N; Desai M; Ways K; Meininger G Diabetes Care; 2016 Jan; 39(1):e19. PubMed ID: 26696666 [No Abstract] [Full Text] [Related]
33. [Does a reduced kidney function (creatinine clearance 10-15 ml/min), without acidosis, increase the risk for the rise of lactic acidosis caused by metformin?]. Heine RJ Ned Tijdschr Geneeskd; 2002 Nov; 146(46):2213. PubMed ID: 12583406 [No Abstract] [Full Text] [Related]
34. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651 [TBL] [Abstract][Full Text] [Related]
35. Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases. Venkatesh B; Moore G; Gill D; Kelly W Crit Care Resusc; 2015 Dec; 17(4):280-2. PubMed ID: 26640065 [No Abstract] [Full Text] [Related]
36. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Blevins TC; Farooki A Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216 [TBL] [Abstract][Full Text] [Related]
37. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. Messana JA; Schwartz SS; Townsend RR Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241 [TBL] [Abstract][Full Text] [Related]